Most Active Drug Stocks: Affymax, Aastrom Biosciences, Vertex Pharmaceuticals Incorporated, Sanofi

Lakeway, TX -- (SBWIRE) -- 02/27/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Affymax, Inc.(NASDAQ:AFFY) jumped 7.11% and is trading at $2.71. Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.

How Should Investors Trade AFFY After The Recent Movement? Find Out Here

Aastrom Biosciences, Inc.(NASDAQ:ASTM) is higher 3.69% and is trading at $1.26. Aastrom Biosciences, Inc. (Aastrom) is a development stage company. The Company is focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is engaged in developing patient-specific, expanded multicellular therapies for uses in the treatment of severe, chronic ischemic cardiovascular diseases.

Is ASTM Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX) jumped 5.98% and is trading at $46.82. Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene.

Is VRTX a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Sanofi SA (ADR)(NYSE:SNY) is higher 0.45% and is trading at $46.49. Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health.

How Should Investors Trade SNY After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.